Have You Taken Tysabri? Understanding PML Risk and Your History
From General Health Information to Occupational Exposure Concerns
If you or a loved one has taken Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Understanding how duration of use, prior immunosuppressant exposure, and JC virus status affect your risk is critical. Building on decades of research into immune-modulating therapies, this page provides a clear overview of what patients need to know about Tysabri and PML.
Understanding Tysabri and Its Association with PML
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is prominently placed in the prescribing information to alert healthcare professionals and patients to the serious nature of this adverse event. PML is caused by the reactivation of the JC virus, which typically remains dormant in immunocompetent individuals. In patients receiving Tysabri, the drug's mechanism of action—blocking the adhesion molecule alpha-4 integrin—impairs immune surveillance in the central nervous system, allowing the virus to replicate and cause demyelination. The clinical presentation of PML can include progressive neurological deficits such as cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis often requires brain imaging, typically magnetic resonance imaging (MRI), and detection of JC virus DNA in cerebrospinal fluid. The FDA label notes that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), underscoring the gravity of this complication.
Risk Factors and Clinical Evidence for PML in Tysabri Patients
Several risk factors for PML in Tysabri-treated patients have been identified. According to the FDA-approved label, these include "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who test positive for anti-JCV antibodies have a higher risk of developing PML, and the risk increases with longer treatment duration, particularly beyond two years. Prior use of immunosuppressive medications further elevates this risk. The label advises that "these factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This risk-benefit assessment is critical for clinicians and patients when deciding to start or continue therapy. The timeline between Tysabri exposure and the development of PML can vary. In clinical trials, PML occurred in three patients: two with multiple sclerosis who were treated for a median of 120 weeks, and one with Crohn's disease after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that PML can emerge after varying durations of therapy, sometimes relatively early. The FDA label emphasizes that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Prompt recognition and cessation of the drug are essential to potentially limit neurological damage, though outcomes remain poor in many cases.
Legal Considerations and the Role of Attorneys
The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The boxed warning and the restricted distribution program, called the TOUCH Prescribing Program, are designed to mitigate risk by ensuring that patients are informed and monitored. The label states that "because of the risk of PML, TYSABRI is available only through a restricted distribution program called the TOUCH Prescribing Program" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients and their families have pursued legal action, alleging that the risks were not adequately communicated or that monitoring was insufficient. For affected individuals, attorney-related considerations may include evaluating whether the prescribing physician or manufacturer provided appropriate warnings and whether the patient's specific risk factors were properly assessed. For patients who develop PML after Tysabri treatment, the consequences are often devastating. The FDA label notes that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Survivors may experience permanent neurological deficits, including cognitive decline, motor impairment, and loss of independence. The adverse event reports from the FDA Adverse Event Reporting System (FAERS) list common symptoms associated with Tysabri use, such as fatigue, headache, gait disturbance, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these are not specific to PML, they highlight the range of neurological issues that patients may experience. In the context of PML, symptoms can progress rapidly, necessitating urgent medical intervention.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the risk of PML with Tysabri?
Tysabri carries a significant risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection that usually leads to death or severe disability. The FDA has issued a boxed warning and requires a restricted distribution program (TOUCH) to manage this risk. Risk factors include anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use.
What should I do if I or a loved one developed PML after Tysabri?
Immediate medical attention is critical. Tysabri should be stopped at the first sign of PML. You may also want to consult an attorney to evaluate whether the risks were adequately communicated and whether legal action is appropriate.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.